Lyell Immunopharma

Q2 FY2026 EarningsQ2 FY26 results slightly beat consensus across key bottom-line metrics: GAAP net loss was $44.8M vs. $45.5M expected, and GAAP EPS was -$1.92 vs. -$2.02 expected. Revenue remains negligible at $4K, marginally exceeding the $3.8K consensus. Operating loss of $47.3M was narrower than the $49.0M anticipated, reflecting disciplined R&D and G&A management despite increased clinical activity for lead candidates ronde-cel and LYL273. The company maintained a solid liquidity position with $228.0M in cash and marketable securities, extending its cash runway into Q3 2027.